Do symbiotic and Vitamin E supplementation have favorite effects in nonalcoholic fatty liver disease? A randomized, double-blind, placebo-controlled trial
Background: Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the world. Oral administration of symbiotic and Vitamin E has been proposed as an effective treatment in NAFLD patients. This study was carried out to assess the effects of symbiotic and/or Vitamin E sup...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2016-01-01
|
| Series: | Journal of Research in Medical Sciences |
| Subjects: | |
| Online Access: | http://www.jmsjournal.net/article.asp?issn=1735-1995;year=2016;volume=21;issue=1;spage=106;epage=106;aulast=Ekhlasi |
| _version_ | 1819067588522541056 |
|---|---|
| author | Golnaz Ekhlasi Roya Kolahdouz Mohammadi Shahram Agah Mitra Zarrati Agha Fatemeh Hosseini Seyed Soroush Soltani Arabshahi Farzad Shidfar |
| author_facet | Golnaz Ekhlasi Roya Kolahdouz Mohammadi Shahram Agah Mitra Zarrati Agha Fatemeh Hosseini Seyed Soroush Soltani Arabshahi Farzad Shidfar |
| author_sort | Golnaz Ekhlasi |
| collection | DOAJ |
| description | Background: Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the world. Oral administration of symbiotic and Vitamin E has been proposed as an effective treatment in NAFLD patients. This study was carried out to assess the effects of symbiotic and/or Vitamin E supplementation on liver enzymes, leptin, lipid profile, and some parameters of insulin resistance (IR) in NAFLD patients. Materials and Methods: We randomly assigned sixty NAFLD adult patients to receive (1) symbiotic twice daily + Vitamin E-like placebo capsule; (2) 400 IU/d Vitamin E + symbiotic-like placebo; (3) symbiotic twice daily + 400 IU/d Vitamin E; and (4) symbiotic-like placebo + Vitamin E-like placebo for 8 weeks. Results: Symbiotic plus Vitamin E supplementation led to a significant decrease in concentrations of liver transaminase (P ≤ 0.05). Mean difference of apolipoprotein A-1 was more significant in symbiotic group compared to control. However, mean difference of apolipoprotein B100/A-1 was only significant in symbiotic group compared to control. At the end of the study, significant differences in total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) were seen between the symbiotic plus Vitamin E and control groups (P < 0.001). Furthermore, intake of symbiotic plus Vitamin E supplements led to a significant decrease in concentrations of triglycerides (TG) after the intervention. Significant differences in leptin, fasting blood sugar (FBS), and insulin levels were seen between the symbiotic plus Vitamin E and control groups at the end of the study (P < 0.001). In contrast, symbiotic and/or Vitamin E supplementation did not affect high-density lipoprotein cholesterol and homeostasis model assessment for IR levels. Conclusion: In our study, symbiotic plus Vitamin E supplementation was the most effective treatment in lowering liver enzymes, leptin, FBS, insulin, TG, TC, and LDL-C among NAFLD patients. |
| first_indexed | 2024-12-21T16:20:38Z |
| format | Article |
| id | doaj.art-ef445486ad374846b8e9a426cbb31725 |
| institution | Directory Open Access Journal |
| issn | 1735-1995 1735-7136 |
| language | English |
| last_indexed | 2024-12-21T16:20:38Z |
| publishDate | 2016-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Journal of Research in Medical Sciences |
| spelling | doaj.art-ef445486ad374846b8e9a426cbb317252022-12-21T18:57:35ZengWolters Kluwer Medknow PublicationsJournal of Research in Medical Sciences1735-19951735-71362016-01-0121110610610.4103/1735-1995.193178Do symbiotic and Vitamin E supplementation have favorite effects in nonalcoholic fatty liver disease? A randomized, double-blind, placebo-controlled trialGolnaz EkhlasiRoya Kolahdouz MohammadiShahram AgahMitra ZarratiAgha Fatemeh HosseiniSeyed Soroush Soltani ArabshahiFarzad ShidfarBackground: Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the world. Oral administration of symbiotic and Vitamin E has been proposed as an effective treatment in NAFLD patients. This study was carried out to assess the effects of symbiotic and/or Vitamin E supplementation on liver enzymes, leptin, lipid profile, and some parameters of insulin resistance (IR) in NAFLD patients. Materials and Methods: We randomly assigned sixty NAFLD adult patients to receive (1) symbiotic twice daily + Vitamin E-like placebo capsule; (2) 400 IU/d Vitamin E + symbiotic-like placebo; (3) symbiotic twice daily + 400 IU/d Vitamin E; and (4) symbiotic-like placebo + Vitamin E-like placebo for 8 weeks. Results: Symbiotic plus Vitamin E supplementation led to a significant decrease in concentrations of liver transaminase (P ≤ 0.05). Mean difference of apolipoprotein A-1 was more significant in symbiotic group compared to control. However, mean difference of apolipoprotein B100/A-1 was only significant in symbiotic group compared to control. At the end of the study, significant differences in total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) were seen between the symbiotic plus Vitamin E and control groups (P < 0.001). Furthermore, intake of symbiotic plus Vitamin E supplements led to a significant decrease in concentrations of triglycerides (TG) after the intervention. Significant differences in leptin, fasting blood sugar (FBS), and insulin levels were seen between the symbiotic plus Vitamin E and control groups at the end of the study (P < 0.001). In contrast, symbiotic and/or Vitamin E supplementation did not affect high-density lipoprotein cholesterol and homeostasis model assessment for IR levels. Conclusion: In our study, symbiotic plus Vitamin E supplementation was the most effective treatment in lowering liver enzymes, leptin, FBS, insulin, TG, TC, and LDL-C among NAFLD patients.http://www.jmsjournal.net/article.asp?issn=1735-1995;year=2016;volume=21;issue=1;spage=106;epage=106;aulast=EkhlasiLeptinlipid profilenonalcoholic fatty liver diseasesymbioticVitamin E |
| spellingShingle | Golnaz Ekhlasi Roya Kolahdouz Mohammadi Shahram Agah Mitra Zarrati Agha Fatemeh Hosseini Seyed Soroush Soltani Arabshahi Farzad Shidfar Do symbiotic and Vitamin E supplementation have favorite effects in nonalcoholic fatty liver disease? A randomized, double-blind, placebo-controlled trial Journal of Research in Medical Sciences Leptin lipid profile nonalcoholic fatty liver disease symbiotic Vitamin E |
| title | Do symbiotic and Vitamin E supplementation have favorite effects in nonalcoholic fatty liver disease? A randomized, double-blind, placebo-controlled trial |
| title_full | Do symbiotic and Vitamin E supplementation have favorite effects in nonalcoholic fatty liver disease? A randomized, double-blind, placebo-controlled trial |
| title_fullStr | Do symbiotic and Vitamin E supplementation have favorite effects in nonalcoholic fatty liver disease? A randomized, double-blind, placebo-controlled trial |
| title_full_unstemmed | Do symbiotic and Vitamin E supplementation have favorite effects in nonalcoholic fatty liver disease? A randomized, double-blind, placebo-controlled trial |
| title_short | Do symbiotic and Vitamin E supplementation have favorite effects in nonalcoholic fatty liver disease? A randomized, double-blind, placebo-controlled trial |
| title_sort | do symbiotic and vitamin e supplementation have favorite effects in nonalcoholic fatty liver disease a randomized double blind placebo controlled trial |
| topic | Leptin lipid profile nonalcoholic fatty liver disease symbiotic Vitamin E |
| url | http://www.jmsjournal.net/article.asp?issn=1735-1995;year=2016;volume=21;issue=1;spage=106;epage=106;aulast=Ekhlasi |
| work_keys_str_mv | AT golnazekhlasi dosymbioticandvitaminesupplementationhavefavoriteeffectsinnonalcoholicfattyliverdiseasearandomizeddoubleblindplacebocontrolledtrial AT royakolahdouzmohammadi dosymbioticandvitaminesupplementationhavefavoriteeffectsinnonalcoholicfattyliverdiseasearandomizeddoubleblindplacebocontrolledtrial AT shahramagah dosymbioticandvitaminesupplementationhavefavoriteeffectsinnonalcoholicfattyliverdiseasearandomizeddoubleblindplacebocontrolledtrial AT mitrazarrati dosymbioticandvitaminesupplementationhavefavoriteeffectsinnonalcoholicfattyliverdiseasearandomizeddoubleblindplacebocontrolledtrial AT aghafatemehhosseini dosymbioticandvitaminesupplementationhavefavoriteeffectsinnonalcoholicfattyliverdiseasearandomizeddoubleblindplacebocontrolledtrial AT seyedsoroushsoltaniarabshahi dosymbioticandvitaminesupplementationhavefavoriteeffectsinnonalcoholicfattyliverdiseasearandomizeddoubleblindplacebocontrolledtrial AT farzadshidfar dosymbioticandvitaminesupplementationhavefavoriteeffectsinnonalcoholicfattyliverdiseasearandomizeddoubleblindplacebocontrolledtrial |